Artios Pharma

About:

Artios Pharma is a independent DNA Damage Response company with a strong pipeline of novel cancer therapies.

Website: https://www.artiospharma.com/

Twitter/X: artiospharma

Top Investors: Andera Partners, AbbVie, Invus, RTW Investments, IP Group

Description:

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.